论文部分内容阅读
目的 :观察低分子肝素治疗急性胰腺炎高凝状态的有效性和安全性。方法 :伴高凝状态的 12 0例急性出血性坏死性胰腺炎 (AHNP)随机分为低分子肝素组和对照组。对照组给予抑制胰酶分泌、抑制胰酶活性、镇静止痛、纠正水电解质平衡等治疗。低分子肝素组在上述治疗基础上 ,加低分子肝素 5 0 0 0IU皮下注射 ,每天 2次。结果 :治疗 2周后低分子肝素组活性Ⅹ因子 (FⅩa)、血浆纤维蛋白原 (FIB)、D 二聚体浓度明显降低 ,其中FⅩa活性、D 二聚体浓度变化与对照组差异有显著性 (P <0 .0 0 1)。血清淀粉酶的降低明显 ,但与对照组差异无显著性 (P >0 .0 5 )。低分子肝素组出现皮下瘀斑 6例。结论 :低分子肝素可明显改善AHNP高凝状态 ,值得推荐使用
Objective: To observe the effectiveness and safety of low molecular weight heparin in the treatment of hypercoagulable state of acute pancreatitis. Methods: A total of 120 acute hemorrhagic necrotizing pancreatitis (AHNP) patients with hypercoagulable state were randomly divided into low molecular weight heparin group and control group. Control group was given to inhibit pancreatic enzyme secretion, inhibit pancreatic enzyme activity, sedative and analgesic, correct water and electrolyte balance and other treatment. Low molecular weight heparin group based on the above treatment, plus low molecular weight heparin subcutaneous injection of 50,000 IU, 2 times a day. Results: After 2 weeks of treatment, the concentrations of FⅩa, FIB and D dimers in low molecular weight heparin group were significantly lower than those in control group, and the changes in FⅩa activity and D dimer concentration were significantly different from those in control group (P <0. 0 0 1). Serum amylase decreased significantly, but no significant difference with the control group (P> 0.05). Low molecular weight heparin subcutaneous ecchymosis in 6 cases. Conclusion: Low molecular weight heparin can significantly improve the hypercoagulability of AHNP, which is recommended